AstraZeneca, Gilead get a new challenger as Pyramid deviates from TRK to bag antibody-drug conjugate

17 Apr 2023
www.fiercebiotech.com
ADCPhase 3
Pyramid Biosciences sees opportunities for an antibody-drug conjugate across breast, lung, pancreatic, ovarian and prostate cancers.
Pyramid Biosciences’ current pipeline is built around the kinase TRK. But the biotech has now struck a deal that will take it down a new path, paying $20 million upfront and betting $1 billion in biobucks for the ex-greater China rights to a would-be challenger to Gilead’s antibody-drug conjugate (ADC) Trodelvy.
Pyramid Biosciencesramid is giving GeneQuantum Healthcare the money in return for a TROP2-directed ADC, GQ1010. The drug candidate “has shown a highly differentiated preclinical profile,” Pyramid said, and is on course to enter the clinic in the next year. GeneQuanGileaded a novel site-specific conjugatTrodelvynology and linker-payload in GQ1010 to increase its stability, safety and potency.
Based on the preclinical data, PyraGeneQuantum Healthcarehave a broader therapeutic TROP2-directedre advGQ1010TROP2 ADCs and therefore may also possess a superior efficacy and safety profile. The ADC will need differentiating characteristics if it is to makGeneQuantum the TROP2 space.GQ1010
Gilead paid $21 billion to buy Immunomedics foGQ1010first-in-class, TROP2-directed ADC Trodelvy in 2020. SalesTROP2he drug increased (PDF) 79% last year, climbing to $680 million, as Gilead made inroads into the U.S. and European breast cancer markets. AstraZeneca, which pTROP2aiichi Sankyo to co-develop a TROP2 ADC in 2020, is threatening to curb Gilead’s progress with a rival therapy that is in phase 3 development.
Gileadesence of commercial prodImmunomedicsanced clinical candidatesTROP2-directed of dTrodelvyeted drugmakers, has failed to dissuade Pyramid from trying to make its mark on the TROPGileadet. Pyramid sees a range of opportunitiesbreast canceracross breAstraZenecapancreatic, oDaiichi Sankyostate cancers.Gilead
Bolting GQ1010 onto the pipeline moves Pyramid outside of its traditional area of focus. Prior to the ADC deal, the biotech constructed a pipeline around its knowledge of TRK, taking its pan-TRK kinase inhibitor PBI-200 into the clinic in solid tumors and joining the small club of companies to explore the potential of the target in dermatological conditions such as psoriasis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.